[1]
Glanz V, Myasoedova V, Sukhorukov V, Grechko A, Zhang D, Orekhov A. Transcriptional characteristics of activated macrophages. Curr Pharm Des 2019; 25(3): 213-7.
[2]
Shalimova A, Fadieienko G, Kolesnikova O, et al. The role of genetic polymorphism in the formation of arterial hypertension, type 2 diabetes and their comorbidity. Curr Pharm Des 2019; 25(3): 218-27.
[3]
Accardi G, Aprile S, Candore G, et al. Genotypic and phenotypic aspects of longevity: results from a Sicilian survey and implication for the prevention and the treatment of age-related diseases. Curr Pharm Des 2019; 25(3): 228-35.
[4]
Liu C, Sun Y, Shao Z. Current concepts of the pathogenesis of aplastic anemia. Curr Pharm Des 2019; 25(3): 236-41.
[5]
Shibata K, Hashimoto T, Miyazaki T, Miyazaki A, Nobe K. Thrombolytic therapy for acute ischemic stroke: Past and future. Curr Pharm Des 2019; 25(3): 242-50.
[6]
Gusev EY, Zotova NV. Cellular stress and general pathological processes. Curr Pharm Des 2019; 25(3): 251-97.
[7]
Kim DV, Makarova AV, Miftakhova RR, Zharkov DO. Base excision DNA repair deficient cells: From disease models to genotoxicity sensors. Curr Pharm Des 2019; 25(3): 298-312.
[8]
Yamagishi S, Koga Y, Sotokawauchi A, et al. Therapeutic potential of pigment epithelium-derived factor in cancer. Curr Pharm Des 2019; 25(3): 313-24.
[9]
Wan D, Wu Q, Ni H, Liu G, Ruan Z, Yin Y. Treatments for iron deficiency (ID): Prospective organic iron fortification. Curr Pharm Des 2019; 25(3): 325-32.
[10]
Shahcheraghi SH, Zangui M, Lotfi M, et al. Therapeutic potential of curcumin in the treatment of glioblastoma multiforme. Curr Pharm Des 2019; 25(3): 333-42.
[11]
Guo H-L, Jing X, Sun J-Y, et al. Valproic acid and the liver injury in patients with epilepsy: an update. Curr Pharm Des 2019; 25(3): 343-51.